C9orf72 突变携带者症状前颈髓病理:纵向神经影像研究
该前瞻性研究纳入 72 名 ALS 和 FTD 患者的一级亲属(40 名为 C9orf72 致病突变携带者),进行颈髓定量 MRI 基线和 18 个月随访。结果显示 40 岁以上 C9+ 携带者基线即存在显著颈髓白质萎缩,18 个月随访出现皮质脊髓束 FA 下降,提示颈髓 MRI 可捕捉症状前病理改变。
要点
- 40 岁以上无症状 C9orf72 携带者基线可见颈髓白质萎缩。
- 18 个月随访出现皮质脊髓束 FA 显著下降。
- 家族史为 ALS 的 40 岁以上携带者基线即有 CST FA 降低。
核心结论
- 颈髓 MRI 可在 40 岁以上 C9orf72 携带者中检出症状前白质萎缩,18 个月随访可见皮质脊髓束 FA 进行性下降。
研究设计与样本
- 前瞻性研究纳入 72 名 ALS 和 FTD 患者的一级亲属,其中 40 名为 C9orf72 致病突变携带者(C9+)。
- 所有受试者接受颈髓定量 MRI,评估结构灰质和白质指标及弥散参数,基线及 18 个月后各一次。
主要发现
- 基线时,40 岁以上 C9+ 受试者各颈椎层面均检出显著白质萎缩,灰质和弥散张量成像参数无相应改变。
- 18 个月随访时,白质萎缩伴随皮质脊髓束 FA 显著下降。
- 40 岁以上无症状 C9+ 受试者若有 ALS 家族史(而非 FTD),基线时也表现出显著皮质脊髓束 FA 降低。
临床怎么用
- 颈髓 MRI 可作为 C9orf72 相关疾病症状前病理改变的影像学标志物。
- 对 40 岁以上 C9orf72 携带者,可考虑颈髓定量 MRI 监测白质萎缩和皮质脊髓束 FA 变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: C9orf72 hexanucleotide repeats expansions account for almost half of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases. Recent imaging studies in asymptomatic C9orf72 carriers have demonstrated cerebral white (WM) and gray matter (GM) degeneration before the age of 40 years. The objective of this study was to characterize cervical spinal cord (SC) changes in asymptomatic C9orf72 hexanucleotide carriers. METHODS: Seventy-two asymptomatic individuals were enrolled in a prospective study of first-degree relatives of ALS and FTD patients carrying the c9orf72 hexanucleotide expansion. Forty of them carried the pathogenic mutation (C9+ ). Each subject underwent quantitative cervical cord imaging. Structural GM and WM metrics and diffusivity parameters were evaluated at baseline and 18 months later. Data were analyzed in C9+ and C9- subgroups, and C9+ subjects were further stratified by age. RESULTS: At baseline, significant WM atrophy was detected at each cervical vertebral level in C9+ subjects older than 40 years without associated changes in GM and diffusion tensor imaging parameters. At 18-month follow-up, WM atrophy was accompanied by significant corticospinal tract (CST) fractional anisotropy (FA) reductions. Intriguingly, asymptomatic C9+ subjects older than 40 years with family history of ALS (as opposed to FTD) also exhibited significant CST FA reduction at baseline. INTERPRETATION: Cervical SC imaging detects WM atrophy exclusively in C9+ subjects older than 40 years, and progressive CST FA reductions can be identified on 18-month follow-up. Cervical SC magnetic resonance imaging readily captures presymptomatic pathological changes and disease propagation in c9orf72-associated conditions. ANN NEUROL 2019;86:158-167.
引用
- Querin G, Bede P, El Mendili MM, et al. Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study. Ann Neurol. 2019. PMID: 31177556. doi:10.1002/ana.25520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。